How do you pull off a successful biotech IPO? With patience, preparation, and no fear of failure.
Last week, I recapped our latest biotech event, “Boston’s Life Science Disruptors.” Attendees at the Novartis Institutes for Biomedical Research got a behind-the-scenes look at the ups and downs faced by three local biotechs—Zafgen, Epizyme, and Sage Therapeutics—on their way to successful Nasdaq debuts.
Today, I’m circling back with a slideshow look at the proceedings, with a tip of the cap to Tyler Trahan for the photos.
Once again, thanks to our speakers, our event host Novartis and our sponsors BDO, Cubist Pharmaceuticals, Health Advances, Icon, Johnson & Johnson Innovation, and Mintz Levin Cohn Ferris Glovsky and Popeo. With that, on with the slideshow.
Author: Ben Fidler
Ben is former Xconomy Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
View all posts by Ben Fidler
